Abstract
Cerebellar ataxias are a group of disabling neurological disorders. Patients exhibit a cerebellar syndrome and can also present with extra-cerebellar deficits, namely pigmentary retinopathy, extrapyramidal movement disorders, pyramidal signs, cortical symptoms (seizures, cognitive impairment/behavioural symptoms), and peripheral neuropathy. Recently, deficits in cognitive operations have been unraveled. Cerebellar ataxias are heterogeneous both at the phenotypic and genotypic point of view. Therapeutical trials performed during these last 4 decades have failed in most cases, in particular because drugs were not targeting a deleterious pathway, but were given to counteract putative defects in neurotransmission. The identification of the causative mutations of many hereditary ataxias, the development of relevant animal models and the recent identifications of the molecular mechanisms underlying ataxias are impacting on the development of new drugs. We provide an overview of the pharmacological treatments currently used in the clinical practice and we discuss the drugs under development.
Keywords: Cerebellum, ataxias, dominant, recessive, X-linked, therapy
Current Neuropharmacology
Title: Past, Present and Future Therapeutics for Cerebellar Ataxias
Volume: 8 Issue: 1
Author(s): D. Marmolino and M. Manto
Affiliation:
Keywords: Cerebellum, ataxias, dominant, recessive, X-linked, therapy
Abstract: Cerebellar ataxias are a group of disabling neurological disorders. Patients exhibit a cerebellar syndrome and can also present with extra-cerebellar deficits, namely pigmentary retinopathy, extrapyramidal movement disorders, pyramidal signs, cortical symptoms (seizures, cognitive impairment/behavioural symptoms), and peripheral neuropathy. Recently, deficits in cognitive operations have been unraveled. Cerebellar ataxias are heterogeneous both at the phenotypic and genotypic point of view. Therapeutical trials performed during these last 4 decades have failed in most cases, in particular because drugs were not targeting a deleterious pathway, but were given to counteract putative defects in neurotransmission. The identification of the causative mutations of many hereditary ataxias, the development of relevant animal models and the recent identifications of the molecular mechanisms underlying ataxias are impacting on the development of new drugs. We provide an overview of the pharmacological treatments currently used in the clinical practice and we discuss the drugs under development.
Export Options
About this article
Cite this article as:
Marmolino D. and Manto M., Past, Present and Future Therapeutics for Cerebellar Ataxias, Current Neuropharmacology 2010; 8 (1) . https://dx.doi.org/10.2174/157015910790909476
DOI https://dx.doi.org/10.2174/157015910790909476 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Botulinum Toxin as a Neuro-Relearning Drug Tool in Motor Paralytic Disorders
Current Drug Therapy Three-Dimensional Electron Cryomicroscopy of Ribosomes
Current Protein & Peptide Science Drug Induced QT Prolongation: Lessons from Congenital and Acquired Long QT Syndromes
Current Drug Targets - Cardiovascular & Hematological Disorders Cardiac (myo)fibroblast: Novel Strategies for its Targeting Following Myocardial Infarction
Current Pharmaceutical Design Alzheimers Disease - An Interactive Perspective
Current Alzheimer Research Therapeutic Agents for Alzheimers Disease
Current Medicinal Chemistry - Central Nervous System Agents Safety and Efficacy of Dexamethasone Intravitreal Implant (Ozurdex) for the Treatment of Persistent Macular Edema Secondary to Retinal Vein Occlusion in Eyes Previously Treated with Anti-Vascular Endothelial Growth Factors
Current Drug Safety mTOR, a Potential Target to Treat Autism Spectrum Disorder
CNS & Neurological Disorders - Drug Targets 4Aβ1-15-Derived Monoclonal Antibody Reduces More Aβ Burdens and Neuroinflammation than Homologous Vaccine in APP/PS1 Mice
Current Alzheimer Research History, Prevalence and Assessment of Limited Joint Mobility, from Stiff Hand Syndrome to Diabetic Foot Ulcer Prevention: A Narrative Review of the Literature
Current Diabetes Reviews Multidrug Resistance Through the Spectacle of P-Glycoprotein
Current Cancer Drug Targets Aerobic Exercise for Preventing Osteoporosis in Postmenopausal Women: an Update of its Effect on Bone Mineral Density
Current Rheumatology Reviews Current Management of Obstetric Fistula: Implication for the Low Resource Areas
Current Women`s Health Reviews Nonmuscle Myosin Heavy Chain and Histone H3 are Intracellular Binding Partners of Lithospermic Acid B and Mediate its Antiproliferative Effect on VSMCs
Current Medicinal Chemistry Rosuvastatin Induced Rhabdomyolysis in a Low Risk Patient: A Case Report and Review of the Literature
Current Clinical Pharmacology Pharmacoperones: A New Therapeutic Approach for Diseases Caused By Misfolded G Protein-Coupled Receptors
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Global View on Rare Diseases: A Mini Review
Current Medicinal Chemistry Motor and Sensory Dysfunction in Musician's Dystonia
Current Neuropharmacology The Urokinase Plasminogen Activator System: A Target for Anti-Cancer Therapy
Current Cancer Drug Targets Nano-Enabled Tribological Thin Film Coatings: Global Patent Scenario
Recent Patents on Nanotechnology